CY1108446T1 - NON-NEUROTOTOXIC PLASMINOGEN ACTIVATORS AGENTS FOR APLICATION TREATMENT - Google Patents
NON-NEUROTOTOXIC PLASMINOGEN ACTIVATORS AGENTS FOR APLICATION TREATMENTInfo
- Publication number
- CY1108446T1 CY1108446T1 CY20081101193T CY081101193T CY1108446T1 CY 1108446 T1 CY1108446 T1 CY 1108446T1 CY 20081101193 T CY20081101193 T CY 20081101193T CY 081101193 T CY081101193 T CY 081101193T CY 1108446 T1 CY1108446 T1 CY 1108446T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- neurototoxic
- aplication
- plasminogen activators
- agents
- Prior art date
Links
- 102000001938 Plasminogen Activators Human genes 0.000 title 1
- 108010001014 Plasminogen Activators Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229940127126 plasminogen activator Drugs 0.000 title 1
- 208000006011 Stroke Diseases 0.000 abstract 2
- 241000288900 Desmodus rotundus Species 0.000 abstract 1
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 231100000501 nonneurotoxic Toxicity 0.000 abstract 1
- ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
Abstract
Η εφεύρεση αναφέρεται στη χρήση και στην παραγωγή μη νευροτοξικών παραγόντων ενεργοποίησης πλασμινογόνου, για παράδειγμα από Desmodus rotundus (DSPA), για τη θεραπευτική αντιμετώπιση της αποπληξίας σε ανθρώπους, για τη διάθεση νέας θεραπευτικής προσέγγισης για την αντιμετώπιση της αποπληξίας σε ανθρώπους.The invention relates to the use and production of non-neurotoxic plasminogen activating agents, for example from Desmodus rotundus (DSPA), for the treatment of stroke in humans, to provide a novel therapeutic approach for the treatment of stroke in humans.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10153601A DE10153601A1 (en) | 2001-11-02 | 2001-11-02 | DSPA for the treatment of stroke |
EP01130006A EP1308166B1 (en) | 2001-11-02 | 2001-12-17 | Non-neurotoxic plasminogen activating factors for treating stroke |
EP02785348A EP1441757B1 (en) | 2001-11-02 | 2002-10-31 | Non-neurotoxic plasminogen activating factors for treating stroke |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108446T1 true CY1108446T1 (en) | 2014-04-09 |
Family
ID=7704253
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101193T CY1108446T1 (en) | 2001-11-02 | 2008-10-23 | NON-NEUROTOTOXIC PLASMINOGEN ACTIVATORS AGENTS FOR APLICATION TREATMENT |
CY20091101206T CY1109648T1 (en) | 2001-11-02 | 2009-11-19 | NON-NEUROTOTOXIC PLASMINOGEN ACTIVATORS FACTORS FOR BRAIN INTERVENTION |
CY20121100407T CY1112957T1 (en) | 2001-11-02 | 2012-04-30 | NON-NEUROTOTOXIC FACTORS, WHICH INCLUDE PLASMINOGENE FOR TREATMENT INTRODUCTION |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091101206T CY1109648T1 (en) | 2001-11-02 | 2009-11-19 | NON-NEUROTOTOXIC PLASMINOGEN ACTIVATORS FACTORS FOR BRAIN INTERVENTION |
CY20121100407T CY1112957T1 (en) | 2001-11-02 | 2012-04-30 | NON-NEUROTOTOXIC FACTORS, WHICH INCLUDE PLASMINOGENE FOR TREATMENT INTRODUCTION |
Country Status (27)
Country | Link |
---|---|
US (7) | US20050048027A1 (en) |
EP (4) | EP1308166B1 (en) |
JP (2) | JP5004407B2 (en) |
KR (3) | KR20070087248A (en) |
CN (2) | CN100446810C (en) |
AT (3) | ATE440614T1 (en) |
AU (1) | AU2002350660C1 (en) |
BR (1) | BR0213856A (en) |
CA (1) | CA2465792C (en) |
CY (3) | CY1108446T1 (en) |
DE (3) | DE10153601A1 (en) |
DK (3) | DK1308166T3 (en) |
EA (3) | EA201000386A1 (en) |
ES (3) | ES2332576T3 (en) |
HK (1) | HK1057328A1 (en) |
HR (1) | HRP20040383B1 (en) |
HU (1) | HU230163B1 (en) |
IL (1) | IL205695A0 (en) |
MX (1) | MXPA04004155A (en) |
NO (1) | NO329789B1 (en) |
NZ (2) | NZ532903A (en) |
PL (1) | PL208343B1 (en) |
PT (3) | PT1308166E (en) |
SG (1) | SG148034A1 (en) |
SI (2) | SI1997510T1 (en) |
WO (1) | WO2003037363A2 (en) |
ZA (1) | ZA200403285B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10153601A1 (en) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA for the treatment of stroke |
US20080057050A1 (en) * | 2003-05-02 | 2008-03-06 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
KR101212631B1 (en) * | 2003-05-02 | 2012-12-14 | 하. 룬드벡 아크티에셀스카브 | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
WO2004096267A1 (en) * | 2003-05-02 | 2004-11-11 | Paion Gmbh | Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke |
US20060135425A1 (en) * | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
US20080213244A1 (en) * | 2003-05-05 | 2008-09-04 | Wolfgang Sohngen | Glutamate Receptor Antagonists as Neuroprotectives |
DE10342518A1 (en) * | 2003-09-12 | 2005-05-12 | Paion Gmbh | Plasminogen activators with reduced lysine binding capacity |
JP2006241109A (en) * | 2005-03-04 | 2006-09-14 | Paion Deutschland Gmbh | FUSION PROTEIN CONTAINING ANTIBODY AGAINST HUMAN P SELECTIN AND DSPAalpha1 |
TWI482628B (en) * | 2007-10-18 | 2015-05-01 | Lundbeck & Co As H | Novel patient subgroups for thrombolysis |
EP2558580A2 (en) | 2010-04-16 | 2013-02-20 | H. Lundbeck A/S | Method for the manufacture of recombinant dspa alpha1 |
EP2661493B1 (en) * | 2011-01-05 | 2016-03-30 | ThromboGenics N.V. | Plasminogen and plasmin variants |
JP6000353B2 (en) | 2011-08-12 | 2016-09-28 | スロンボジェニックス・ナムローゼ・フェンノートシャップThromboGenics NV | Plasminogen and plasmin variants |
BR112021012601A2 (en) * | 2018-12-28 | 2021-11-30 | Catalyst Biosciences Inc | Modified urokinase-type plasminogen activating polypeptides and methods of use |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL68561A (en) | 1982-05-05 | 1991-01-31 | Genentech Inc | Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof |
US4766075A (en) * | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US5244806A (en) * | 1985-08-26 | 1993-09-14 | Eli Lilly And Company | DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells |
DE3643158A1 (en) | 1986-04-21 | 1987-11-19 | Boehringer Mannheim Gmbh | TISSUE PLASMINOGEN ACTIVATOR (TPA) DERIVATIVE AND ITS PRODUCTION |
JPH087179B2 (en) * | 1986-09-27 | 1996-01-29 | 日本碍子株式会社 | Gas sensor |
WO1988005081A2 (en) * | 1986-12-30 | 1988-07-14 | Cetus Corporation | Novel plasminogen activator |
IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same |
EP0386240B1 (en) * | 1987-10-29 | 1995-07-19 | Yamanouchi Pharmaceutical Co. Ltd. | Novel polypeptide compounds |
US5094953A (en) | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
IE69054B1 (en) * | 1988-07-20 | 1996-08-07 | Schering Ag | Vampire bat salivary plasminogen activators |
DE3825253A1 (en) | 1988-07-25 | 1990-02-01 | Boehringer Mannheim Gmbh | T-PA DERIVATIVE AND ITS PRODUCTION |
US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
JPH0273774A (en) * | 1988-09-09 | 1990-03-13 | Nec Corp | Facsimile equipment |
GB8901422D0 (en) * | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | New tissue plasminogen activator |
US5676947A (en) * | 1989-02-07 | 1997-10-14 | Boehringer Manneheim Gmbh | Method for treating thromboembolic conditions using thrombolytically active proteins |
DE3903581A1 (en) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | FABRIC PLASMINOGEN ACTIVATOR DERIVATIVE |
WO1990009438A1 (en) * | 1989-02-13 | 1990-08-23 | Schering Aktiengesellschaft Berlin Und Bergkamen | Novel thrombolytic |
DE3904580A1 (en) | 1989-02-13 | 1990-08-16 | Schering Ag | Thrombolytic agent |
DE3917949A1 (en) * | 1989-05-30 | 1991-01-24 | Schering Ag | New fibrin specific thrombolytic agent v-PA |
US6008019A (en) * | 1989-02-13 | 1999-12-28 | Schering Aktiengesellschaft | Plasminogen activator from saliva of the vampire bat |
US5891664A (en) * | 1989-04-07 | 1999-04-06 | Cancerforskningsfondet Af 1989 | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
DE69033653T2 (en) * | 1989-04-07 | 2001-06-07 | Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen | UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR |
JPH0352119A (en) * | 1989-07-19 | 1991-03-06 | Matsushita Electric Ind Co Ltd | Optical recording and reproducing device |
NL8902454A (en) | 1989-10-03 | 1991-05-01 | Stichting Centraal Lab | MUTANTS OF THE HUMANE PLASMINOGENIC ACTIVATOR INHIBITOR 1 (PAI-1), THEIR PREPARATION AND USE, AND RECOMBINANT POLYNUCLEOTIDES INCLUDING GENETIC INFORMATION CODING FOR THESE MUTANTS. |
US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
WO1992018157A1 (en) * | 1991-04-16 | 1992-10-29 | Boehringer Mannheim Gmbh | Pharmaceutical packaging unit containing plasminogen activators for multiple-bolus administration |
DE4123845A1 (en) * | 1991-07-18 | 1993-01-21 | Boehringer Mannheim Gmbh | Compsn. for treating thromboembolic disease with plasminogen activator |
US5595736A (en) * | 1991-04-22 | 1997-01-21 | Eli Lilly And Company | Compounds and methods for treatment of thromboembolic disorders |
NL9101520A (en) * | 1991-09-09 | 1993-04-01 | Stork Fibron Bv | METHOD FOR MANUFACTURING AN EDIBLE PRODUCT |
DE69215537T2 (en) | 1991-12-16 | 1997-04-30 | Genentech, Inc., South San Francisco, Calif. | t-PA SUBSTITUTION VARIANTS WITH IMPROVED FIBRINE SPECIFICITY |
WO1994013807A1 (en) * | 1992-12-04 | 1994-06-23 | Schering Aktiengesellschaft | Clotting inhibitor made from protostomia saliva |
US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
GB9412131D0 (en) * | 1994-06-17 | 1994-08-10 | British Bio Technology | Thrombolytic composition |
DE4423574A1 (en) | 1994-07-05 | 1996-01-11 | Boehringer Mannheim Gmbh | Non-glycosylated plasminogen activator derivatives and their use when there is an increased risk of bleeding |
US5827832A (en) | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
US5786187A (en) * | 1995-09-21 | 1998-07-28 | The Research Foundation Of State University Of New York | Method for reducing neuronal degeneration associated with seizure |
US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
US20020081294A1 (en) * | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
US5731186A (en) | 1996-02-05 | 1998-03-24 | Schering Aktiengesellschaft | Method for the production of rDSPA α1 |
US6235947B1 (en) * | 1997-04-14 | 2001-05-22 | Takeda Chemical Industries, Ltd. | D-mannitol and its preparation |
US5830349A (en) * | 1996-07-22 | 1998-11-03 | Dana Corporation | Flow inverter for filters |
BR9711840A (en) * | 1996-10-01 | 1999-08-24 | Univ Georgia Res Found | Biological insect control agents expressing genes for expensive toxins specific to m-all insects and compositions |
US6008109A (en) * | 1997-12-19 | 1999-12-28 | Advanced Micro Devices, Inc. | Trench isolation structure having a low K dielectric encapsulated by oxide |
KR20010069066A (en) * | 2000-01-12 | 2001-07-23 | 이종원 | Culturing Method Which Allows Growth of Animal Cells Under Hypoxic Condition |
DE10008646A1 (en) | 2000-02-24 | 2001-09-13 | Kempten Elektroschmelz Gmbh | Molded body used as a cooking plate comprises an adhesion- and scratch-resistant surface coating made of glass and/or glass-ceramic formed on hot-pressed, gas pressure-sintered , reaction-bound or hot isostatically pressed silicon nitride |
GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
US20020089179A1 (en) * | 2000-12-30 | 2002-07-11 | Levon Guyumjan | Hose coupling apparatus and method |
DE10153601A1 (en) | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA for the treatment of stroke |
US20060135425A1 (en) * | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
US20080057050A1 (en) * | 2003-05-02 | 2008-03-06 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
KR101212631B1 (en) | 2003-05-02 | 2012-12-14 | 하. 룬드벡 아크티에셀스카브 | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
WO2004096267A1 (en) | 2003-05-02 | 2004-11-11 | Paion Gmbh | Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke |
US20080213244A1 (en) * | 2003-05-05 | 2008-09-04 | Wolfgang Sohngen | Glutamate Receptor Antagonists as Neuroprotectives |
US20050085478A1 (en) | 2003-08-22 | 2005-04-21 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
DE10342518A1 (en) | 2003-09-12 | 2005-05-12 | Paion Gmbh | Plasminogen activators with reduced lysine binding capacity |
TWI482628B (en) * | 2007-10-18 | 2015-05-01 | Lundbeck & Co As H | Novel patient subgroups for thrombolysis |
-
2001
- 2001-11-02 DE DE10153601A patent/DE10153601A1/en not_active Ceased
- 2001-12-17 DE DE50115077T patent/DE50115077D1/en not_active Expired - Lifetime
- 2001-12-17 ES ES01130006T patent/ES2332576T3/en not_active Expired - Lifetime
- 2001-12-17 PT PT01130006T patent/PT1308166E/en unknown
- 2001-12-17 AT AT01130006T patent/ATE440614T1/en active
- 2001-12-17 DK DK01130006T patent/DK1308166T3/en active
- 2001-12-17 EP EP01130006A patent/EP1308166B1/en not_active Expired - Lifetime
-
2002
- 2002-10-31 AT AT02785348T patent/ATE401910T1/en active
- 2002-10-31 CN CNB028234782A patent/CN100446810C/en not_active Expired - Fee Related
- 2002-10-31 EP EP10011603A patent/EP2368567A1/en not_active Withdrawn
- 2002-10-31 SG SG200604427-5A patent/SG148034A1/en unknown
- 2002-10-31 HU HU0402165A patent/HU230163B1/en not_active IP Right Cessation
- 2002-10-31 DE DE50212548T patent/DE50212548D1/en not_active Expired - Lifetime
- 2002-10-31 CN CNA2007101051509A patent/CN101156948A/en active Pending
- 2002-10-31 ES ES08012976T patent/ES2382224T3/en not_active Expired - Lifetime
- 2002-10-31 EA EA201000386A patent/EA201000386A1/en unknown
- 2002-10-31 WO PCT/EP2002/012204 patent/WO2003037363A2/en active Application Filing
- 2002-10-31 PL PL369872A patent/PL208343B1/en unknown
- 2002-10-31 EA EA200400624A patent/EA010858B1/en not_active IP Right Cessation
- 2002-10-31 PT PT08012976T patent/PT1997510E/en unknown
- 2002-10-31 KR KR1020077017712A patent/KR20070087248A/en active Application Filing
- 2002-10-31 SI SI200230980T patent/SI1997510T1/en unknown
- 2002-10-31 US US10/494,004 patent/US20050048027A1/en not_active Abandoned
- 2002-10-31 PT PT02785348T patent/PT1441757E/en unknown
- 2002-10-31 JP JP2003539706A patent/JP5004407B2/en not_active Expired - Fee Related
- 2002-10-31 DK DK08012976.0T patent/DK1997510T3/en active
- 2002-10-31 CA CA2465792A patent/CA2465792C/en not_active Expired - Fee Related
- 2002-10-31 NZ NZ532903A patent/NZ532903A/en not_active IP Right Cessation
- 2002-10-31 AT AT08012976T patent/ATE547115T1/en active
- 2002-10-31 MX MXPA04004155A patent/MXPA04004155A/en active IP Right Grant
- 2002-10-31 EP EP08012976A patent/EP1997510B1/en not_active Expired - Lifetime
- 2002-10-31 ES ES02785348T patent/ES2311070T3/en not_active Expired - Lifetime
- 2002-10-31 DK DK02785348T patent/DK1441757T3/en active
- 2002-10-31 KR KR1020097025518A patent/KR20090128583A/en not_active Application Discontinuation
- 2002-10-31 EP EP02785348A patent/EP1441757B1/en not_active Expired - Lifetime
- 2002-10-31 BR BR0213856-5A patent/BR0213856A/en not_active Application Discontinuation
- 2002-10-31 NZ NZ545414A patent/NZ545414A/en not_active IP Right Cessation
- 2002-10-31 SI SI200230745T patent/SI1441757T1/en unknown
- 2002-10-31 AU AU2002350660A patent/AU2002350660C1/en not_active Ceased
- 2002-10-31 EA EA200801714A patent/EA013707B1/en not_active IP Right Cessation
- 2002-10-31 KR KR1020047006691A patent/KR100816221B1/en not_active IP Right Cessation
-
2003
- 2003-11-07 HK HK03108108.9A patent/HK1057328A1/en not_active IP Right Cessation
-
2004
- 2004-04-30 ZA ZA200403285A patent/ZA200403285B/en unknown
- 2004-04-30 HR HRP20040383AA patent/HRP20040383B1/en not_active IP Right Cessation
- 2004-06-01 NO NO20042262A patent/NO329789B1/en not_active IP Right Cessation
-
2005
- 2005-12-20 US US11/311,475 patent/US20060142195A1/en not_active Abandoned
-
2008
- 2008-06-27 US US12/163,828 patent/US8071091B2/en not_active Expired - Fee Related
- 2008-08-22 US US12/196,785 patent/US8119597B2/en not_active Expired - Fee Related
- 2008-10-23 CY CY20081101193T patent/CY1108446T1/en unknown
-
2009
- 2009-01-05 JP JP2009000322A patent/JP2009137983A/en not_active Withdrawn
- 2009-11-19 CY CY20091101206T patent/CY1109648T1/en unknown
-
2010
- 2010-05-11 IL IL205695A patent/IL205695A0/en unknown
-
2012
- 2012-02-10 US US13/370,706 patent/US20130039902A1/en not_active Abandoned
- 2012-04-30 CY CY20121100407T patent/CY1112957T1/en unknown
-
2014
- 2014-01-09 US US14/151,390 patent/US20140199287A1/en not_active Abandoned
-
2016
- 2016-03-24 US US15/079,550 patent/US20170051268A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108446T1 (en) | NON-NEUROTOTOXIC PLASMINOGEN ACTIVATORS AGENTS FOR APLICATION TREATMENT | |
CY1106032T1 (en) | SUBSTITUTED PYRAZOLES | |
DE60111570D1 (en) | ISOINDOLIN-1-ON AS GLUCOKINASE ACTIVATORS | |
CY1111237T1 (en) | USE OF PRIMPEXOLIS FOR TREATMENT OF SELF-AUTOMATIC LABORATORY SCIENCE | |
ATE259782T1 (en) | N-CYANOMETHYLAMIDE AS PROTEASE INHIBITORS | |
SE0100901D0 (en) | New composition | |
ATE396738T1 (en) | USE OF GLP-2 PEPTIDES | |
IL156774A0 (en) | Inhibitors of cruzipain and other cysteine proteases | |
WO2003005999A8 (en) | Methods of treating cytokine mediated diseases | |
ATE504315T1 (en) | METHOD FOR EVALUATION OF CD10-ACTIVATED PRODRUG COMPOUNDS | |
CY1108610T1 (en) | IL-2 Peptides and their derivatives and their use as therapeutic agents | |
MXPA03007140A (en) | Chemical compounds. | |
BRPI0413449A (en) | quinoxaline compounds | |
HRP20050903A2 (en) | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke | |
SE0101932D0 (en) | Pharmaceutical combinations | |
BR0017157A (en) | 6-hydroxy-indazole derivatives for the treatment of glaucoma | |
DE60224667D1 (en) | PERYLENEQUINONES FOR USE AS SONOSENSITIZER | |
ATE483714T1 (en) | PODOPHYLLOTOXINS AS ANTIPROLIFERATIVE AGENTS | |
CY1114254T1 (en) | Intravenous injection of non-neurotoxic plasminogen activators to treat cerebral episode | |
BR0314139A (en) | Substituted 1,4-pyrazine derivatives | |
ATE277924T1 (en) | ARYL-8-AZABICYCLO(3.2.1)OCTANES FOR THE TREATMENT OF DEPRESSION | |
AU2002254930A1 (en) | Novel medicament compositions based on anticholinergic agents and endothelin antagonists | |
DK1368023T3 (en) | Use of buprenoprphine to treat urinary incontinence | |
ECSP034454A (en) | CRYSTAL THERAPEUTIC AGENT | |
ATE328082T1 (en) | SHORTENED BARD1 PROTEIN AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |